Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (binding) | = 0.67 uM | Induction of GTP-tubulin polymerization | ChEMBL. | 17263521 |
ED50 (binding) | = 0.67 uM | Induction of GTP-tubulin polymerization | ChEMBL. | 17263521 |
IC50 (functional) | = 12.2 nM | Inhibition of growth in 1A9 cell line after 72 hrs | ChEMBL. | 17263521 |
IC50 (functional) | = 12.2 nM | Inhibition of growth in 1A9 cell line after 72 hrs | ChEMBL. | 17263521 |
IC50 (ADMET) | = 16 nM | Cytotoxicity against PC3 cell line by MTT assay | ChEMBL. | 17263521 |
IC50 (ADMET) | = 16 nM | Cytotoxicity against PC3 cell line by MTT assay | ChEMBL. | 17263521 |
IC50 (ADMET) | = 20 nM | Cytotoxicity against A2780 cell line | ChEMBL. | 17263521 |
IC50 (ADMET) | = 20 nM | Cytotoxicity against A2780 cell line | ChEMBL. | 17263521 |
IC50 (functional) | = 46.4 nM | Inhibition of growth in epothilone A resistant 1A9-A8 Tbeta274I mutant cell line after 72 hrs by SRB assay | ChEMBL. | 17263521 |
IC50 (functional) | = 46.4 nM | Inhibition of growth in epothilone A resistant 1A9-A8 Tbeta274I mutant cell line after 72 hrs by SRB assay | ChEMBL. | 17263521 |
IC50 (functional) | = 157 nM | Inhibition of growth in paclitaxel resistant 1A9-PTX10 Fbeta270V mutant cell line after 72 hrs by SRB assay | ChEMBL. | 17263521 |
IC50 (functional) | = 157 nM | Inhibition of growth in paclitaxel resistant 1A9-PTX10 Fbeta270V mutant cell line after 72 hrs by SRB assay | ChEMBL. | 17263521 |
Ratio IC50 (functional) | = 3.8 | Relative resistance, IC50 for 1A9-A8 A8 Tbeta274I mutant/IC50 for 1A9 | ChEMBL. | 17263521 |
Ratio IC50 (functional) | = 9.2 | Relative resistance, IC50 for 1A9-PTX10 Fbeta270V mutant/IC50 for 1A9 | ChEMBL. | 17263521 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 17263521 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.